急性脑梗死患者经神经节苷脂治疗的临床疗效

Clinical Efficacy of Ganglioside in the Treatment of Patients with Acute Cerebral Infarction

目的:研究神经节苷脂治疗急性脑梗死患者的临床疗效。方法:选取漯河市第二人民医院2019年8月至2021年8月期间收治146例的急性脑梗死患者,根据治疗方法不同分为观察组(78例,神经节苷脂联合阿替普酶治疗)和对照组(68例,阿替普酶治疗)。比较两组患者的临床疗效,不同时期神经功能以及治疗前后炎症因子水平。结果:观察组患者治疗总有效率为91.67%,高于对照组的80.00%,差异具有统计学意义(P<0.05)。两组患者治疗后全血黏度、血浆黏度、红细胞比容及红细胞聚集指数均显著降低,且治疗后观察组患者的全血黏度、血浆黏度、红细胞比容及红细胞聚集指数水平均显著低于对照组,差异具有统计学意义(P<0.05)。治疗后两组患者的C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平均有明显的下降,而治疗后观察组患者的CRP、TNF-α水平均明显低于对照组,差异具有统计学意义(P<0.05)。治疗1周后、治疗2周后两组患者的美国国立卫生研究院卒中量表(NIHSS)评分均有明显的下降,而治疗1周后、治疗2周后观察组患者的NIHSS评分显著低于对照组,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:神经节苷脂联合阿替普酶静脉溶栓治疗更有利于改善急性脑梗死患者的神经功能、血液流变学指标,且较单独使用阿替普酶治疗者可更好的抑制患者炎症反应。

Objective Study the clinical efficacy of ganglioside therapy in patients with acute cerebral infarction.Methods A total of 146 patients with acute cerebral infarction admitted to Luohe Second People's Hospital from August 2019 to August 2021 were selected and divided into an observation group(78 cases,treated with ganglioside combined with alteplase)and a control group(68 cases,treated with alteplase)according to different treatment methods.The clinical efficacy,neurological function at different periods and levels of inflammatory factors before and after treatment were compared between the two groups.Results The total effective rate of the observation group was 91.67%,higher than 80.00% of the control group,the difference was statistically significant(P<0.05).After treatment,whole blood viscosity,plasma viscosity,hematocrit value and red cell assembling index in the two groups were significantly decreased,and the whole blood viscosity,plasma viscosity,hematocrit value and red cell assembling index in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)in the two groups were significantly decreased,and the levels of CRP and TNF-α in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).National Institutes of Health Stroke Scale(NIHSS)scores of patients in both groups decreased significantly after 1 week and 2 weeks of treatment,while NIHSS scores of patients in the observation group were significantly lower than those in the control group after 1 week and 2 weeks of treatment,with statistical significances(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Ganglioside combined with alteplase intravenous thrombolytic therapy is more beneficial to improve the neurological function and hemorheology index of patients with acute cerebral infarction,and can better inhibit the inflammatory response of patients compared with alteplase alone.